Tepezza is a drug
Across the United States, patients who have received Tepezza infusions to treat thyroid eye disease (TED) are stepping forward to file lawsuits after experiencing hearing-related problems, including persistent subjective hearing loss, severe hearing impairment, and permanent hearing loss. By November 2024, the Tepezza multidistrict litigation (MDL) reached a significant milestone, consolidating 191 Tepezza hearing loss…
The Legal And Medical Fallout Of Serious Side Effects Tepezza, a drug developed to treat thyroid eye disease (TED), has recently come under intense scrutiny due to reports of severe side effects. Although the drug was initially celebrated as a breakthrough treatment for the rare autoimmune disorder, patients are now experiencing unintended consequences, such as…
Horizon Therapeutics, a well-established pharmaceutical company, has recently come under significant scrutiny due to complications linked to its drug, Tepezza. Horizon Therapeutics’ Tepezza, approved by the FDA for the treatment of Thyroid Eye Disease (TED), has become a subject of concern as patients report severe and unexpected side effects, particularly hearing loss. This emerging issue…
Tepezza (teprotumumab-trbw) is a medication that has garnered significant medical attention, in recent years, particularly among those dealing with Thyroid Eye Disease (TED). TED is a rare, autoimmune condition that causes inflammation and swelling behind the eyes, leading to symptoms like bulging eyes, double vision, and discomfort. Tepezza, approved by the FDA in 2020, is…
For those grappling with chronic thyroid eye disease (TED), a relatively new prescription medicine, Tepezza, has emerged as a beacon of hope. Tepezza, approved by the FDA in January 2020, promises relief from the debilitating symptoms of TED, including bulging eyes, double vision, and eye pain. What is Tepezza? It is an IGF-1 receptor inhibitor…
Tepezza (teprotumumab) is a medication designed to treat Thyroid Eye Disease (TED), a rare but debilitating condition affecting the eyes and vision. As with many new pharmaceuticals, Tepezza has sparked considerable legal and regulatory discussion. Its journey from approval to market, coupled with emerging litigation, presents a complex landscape for patients and healthcare professionals to…
Tepezza is a marketed intravenous infusion used for treating thyroid eyes. Tepezza are biosimilar drugs that contain active ingredients teptotumumab-trbw. Tepezza has been FDA-authorized for the treatment of TED in adults. The autoimmune disease of TED is triggered when the body attacks healthy tissues by mistake. Thyroidism is usually found in the elderly and is…
Hearing loss can be a devastating experience, affecting nearly every aspect of daily life. Recently, patients who have used Tepezza, a drug prescribed for thyroid eye disease, have reported significant hearing issues, including tinnitus and hearing loss. Tepezza, initially heralded as a breakthrough treatment, now stands at the center of a growing number of lawsuits….
7 May 2024 – The parties are continuing their work to solve problems and to establish a schedule for specialized and general discovery. Apparently, both sides have agreed to hold the investigation to take place between 2024 and 2525. April 18, 2020– Plaintiffs selected their proposed cases and a Defendant’s motion extended. The parties work…
Tepezza Hearing Loss Litigation Update The Tepezza hearing loss litigation has shown sluggish growth, with only 13 new cases added to the MDL throughout April. This brings the total number of pending cases in the Tepezza hearing loss MDL to 113. Key Points: This update highlights the incremental nature of the litigation process and provides…